Ascidian Therapeutics
PrivateLast Round
Series A
Extension
Nov 8, 2023
Total Funding Raised
$90M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Ascidian Therapeutics operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series A Extension round in November 2023.
Ascidian Therapeutics is a biotechnology company developing exon-editing RNA therapeutics that target the root causes of diseases by excising harmful genes and replacing them with healthy ones to restore normal protein production.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ascidian Therapeutics Comparables
Compare Ascidian Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shape Therapeutics | 89% | |
| AIRNA | 85% | |
| Tacit Therapeutics | 85% |
For institutional investors. Book with your work email.
Ascidian Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Nov 8, 2023 | ||||
| Series A | Oct 12, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ascidian Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Apple Tree Partners | Series A, Series A Extension |
| Pathway Bioventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 102% MoM.
For institutional investors. Book with your work email.
Ascidian Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ascidian Therapeutics's valuation, stock price, and market status.
Is Ascidian Therapeutics a public or private company?
Ascidian Therapeutics is a private company.
What is the current stock price of Ascidian Therapeutics?
Ascidian Therapeutics is a private company, so its shares have no public market price. Caplight tracks Ascidian Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ascidian Therapeutics worth (valuation)?
Valuation information for Ascidian Therapeutics is not publicly available.
Can I buy Ascidian Therapeutics stock?
Ascidian Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ascidian Therapeutics's last funding round?
Ascidian Therapeutics's most recent funding round was Series A Extension on November 8, 2023.
Who are the main investors in Ascidian Therapeutics?
Key investors in Ascidian Therapeutics include Apple Tree Partners.
Will Ascidian Therapeutics IPO soon?
No public IPO plans have been announced for Ascidian Therapeutics.
How can I track Ascidian Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Ascidian Therapeutics's shares on secondary markets.